Advanced search
Publication Cover
Postgraduate Medicine Volume 114, 2003 - Issue 1
Submit an article Journal homepage
8
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Current therapies for chronic hepatitis C

Drug combination achieves sustained response in more than half of patients

Keyur Patel Dr Patel is a senior research associate, and Dr McHutchison is director, gastrointestinal and hepatology research, Duke Clinical Research Institute, division of gastroenterology, Duke University Medical Center, Durham, North Carolina.
, MD &
John G. McHutchison Dr Patel is a senior research associate, and Dr McHutchison is director, gastrointestinal and hepatology research, Duke Clinical Research Institute, division of gastroenterology, Duke University Medical Center, Durham, North Carolina.Correspondence[email protected].
, MD
Pages 48-62 | Published online: 30 Jun 2015

References

  • Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8): 556–62
  • Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 Suppl 1): S35–46
  • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21): 1485–92
  • Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon al- pha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138): 1426–32
  • Lau DT, Kleiner DE, Ghany MG, et al. 10-Year follow-up after interferon- alpha therapy for chronic hepatitis C. Hepatology 1998;28(4): 1121–7
  • Poynard T, McHutchison J, Goodman Z, et al. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31(1): 211–8
  • Strader DB. Understudied populations with hepatitis C. Hepatology 2002: 36(5 Suppl 1):S226–36
  • Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36(5 Suppl 1):S179–84
  • Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002: 36(5 Suppl 1):S220–5
  • Lau JY, Tam RC, Liang TJ, et al. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35(5): 1002–9
  • Glue P, Fang JW, Rouzier-Panis R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000:68(5): 556–67
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001: 358(9286):958–65
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13): 975–82
  • Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40KD) in combination with ribavirin: efficacy and safety results from a phase III randomized, double-blind multicenter study examining the effect of duration of treatment and RBV dose. (Abstr) J Hepatol 2002; 36(Suppl 1):3
  • McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123(4): 1061–9
  • Davis GL. Monitoring of viral levels during therapy of hepatitis C. Hepatology 2002; 36(5 Suppl 1): S145–51
  • Jacobson IM, Russo MW, Brown RS Jr, et al. Pegylated interferon alfa- 2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonre-sponders to interferon monotherapy or combination therapy and in combination therapy relapsers. (Abstr) Gastroenterology 2002; 36(5 Suppl 1):A626 Stan
  • Shiffman ML. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. (Abstr) Hepatology 2002; 36(4 Pt 2):295A

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.